These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21130659)

  • 1. Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor.
    Rode HB; Sos ML; Grütter C; Heynck S; Simard JR; Rauh D
    Bioorg Med Chem; 2011 Jan; 19(1):429-39. PubMed ID: 21130659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
    Pawar VG; Sos ML; Rode HB; Rabiller M; Heynck S; van Otterlo WA; Thomas RK; Rauh D
    J Med Chem; 2010 Apr; 53(7):2892-901. PubMed ID: 20222733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
    Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
    Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
    J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
    Ballard P; Bradbury RH; Harris CS; Hennequin LF; Hickinson M; Johnson PD; Kettle JG; Klinowska T; Leach AG; Morgentin R; Pass M; Ogilvie DJ; Olivier A; Warin N; Williams EJ
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1633-7. PubMed ID: 16380259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
    Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
    J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of novel 2,4'-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors.
    Abou-Seri SM
    Eur J Med Chem; 2010 Sep; 45(9):4113-21. PubMed ID: 20580136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).
    Wissner A; Overbeek E; Reich MF; Floyd MB; Johnson BD; Mamuya N; Rosfjord EC; Discafani C; Davis R; Shi X; Rabindran SK; Gruber BC; Ye F; Hallett WA; Nilakantan R; Shen R; Wang YF; Greenberger LM; Tsou HR
    J Med Chem; 2003 Jan; 46(1):49-63. PubMed ID: 12502359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of a series of novel bisquinazoline glycosides as epidermal growth factor receptor inhibitors.
    Chen S; Zhang X; Wang J; Wan S; Geng M; Jiang T
    Chem Biol Drug Des; 2011 Dec; 78(6):1006-13. PubMed ID: 21824331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
    Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of phosphorylated myosin light chain kinase on the ATP-dependent actin-myosin interaction.
    Samizo K; Okagaki T; Kohama K
    Biochem Biophys Res Commun; 1999 Jul; 261(1):95-9. PubMed ID: 10405329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles.
    Wissner A; Hamann PR; Nilakantan R; Greenberger LM; Ye F; Rapuano TA; Loganzo F
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1411-6. PubMed ID: 15006373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
    J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
    Tsou HR; Overbeek-Klumpers EG; Hallett WA; Reich MF; Floyd MB; Johnson BD; Michalak RS; Nilakantan R; Discafani C; Golas J; Rabindran SK; Shen R; Shi X; Wang YF; Upeslacis J; Wissner A
    J Med Chem; 2005 Feb; 48(4):1107-31. PubMed ID: 15715478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
    Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
    Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
    Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
    Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors.
    Pannala M; Kher S; Wilson N; Gaudette J; Sircar I; Zhang SH; Bakhirev A; Yang G; Yuen P; Gorcsan F; Sakurai N; Barbosa M; Cheng JF
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5978-82. PubMed ID: 17827009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.
    Fidanze SD; Erickson SA; Wang GT; Mantei R; Clark RF; Sorensen BK; Bamaung NY; Kovar P; Johnson EF; Swinger KK; Stewart KD; Zhang Q; Tucker LA; Pappano WN; Wilsbacher JL; Wang J; Sheppard GS; Bell RL; Davidsen SK; Hubbard RD
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2452-5. PubMed ID: 20346655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.